Precision Timing: Unveiling the Impact of CDK4/6 Inhibition

Overview
The management of HR+/HER2- early breast cancer (EBC) has traditionally presented clinical challenges due to the prolonged risk of recurrence that can persist for decades. Up to 50% of recurrences occur beyond the first 5 years after initial diagnosis. However, the inclusion of CDK4/6 inhibitors revolutionized the treatment paradigm of HR+/HER2- EBC, and combining these agents with endocrine therapy has yielded significant benefits in terms of progression-free survival, objective response rate, and overall survival in patients with breast cancer. In this educational series, expert faculty evaluate best practices and the supporting clinical data for the use of CDK4/6 inhibitor therapy in HR+/HER2- EBC.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Hope Rugo, MD, FASCO
Professor of Medicine
Winterhof Distinguished Prof of Breast Oncology
University of California
Hellen Diller Family Comprehensive Cancer Center
Dr. Rugo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics
Consulting Fees: Chugai, Mylan, Napo, Puma, Sanofi
Faculty:
Nadia Harbeck MD, PhD
Director, Breast Cancer
Professor, Conservative Oncology
LMU University Hospital
Munich, Germany
Dr. Harbeck has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research (institution): AstraZeneca, Gilead, Lilly, MSD,Roche
Ownership Interests: West German Study Group
Consulting Fees: AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Viatris,Zeullig Pharma
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Wilma Guerra has nothing to disclose.
- Samantha Keehn has nothing to disclose.
- Jennifer Brutsche has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Brad Bongiovanni, ND has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Evaluate evidence from practice-changing phase 3 trials in HR+/HER2- early breast cancer (EBC) and their implications for clinical practice
- Develop evidence- and guideline-driven treatment strategies for high-risk patients with HR+/HER2- EBC
- Implement collaborative, multidisciplinary strategies to promote adherence/persistence while mitigating CDK4/6 inhibitor-related adverse events
- Differentiate therapeutic options for patients with HR+/HER2- EBC based on tumor characteristics, efficacy, and patient preferences
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with breast cancer.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 9/30/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 contact hours/0.125 CEUs of pharmacy contact hours.

The Universal Activity Number for this program is JA0006235-0000-24-096-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving, and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
This activity is supported by an independent educational grant from Eli Lilly and Company.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medcon. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medcon you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 09/30/2024
Expiration Date: 09/30/2025